Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
27 hedge funds and large institutions have $83.7M invested in Sinovac Biotech, Ltd in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 3 closing their positions.
163% more call options, than puts
Call options by funds: $258K | Put options by funds: $98K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
4% less funds holding
Funds holding: 28 → 27 (-1)
10% less capital invested
Capital invested by funds: $93.4M → $83.7M (-$9.76M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$137K |
| 2 |
RQS
Ramsey Quantitative Systems
Louisville,
Kentucky
|
+$88.8K |
| 3 |
Parallax Volatility Advisers
San Francisco,
California
|
+$44.9K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$40.3K |
| 5 |
YMRC
Yorktown Management & Research Company
Forest,
Virginia
|
+$37.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$619K |
| 2 |
Renaissance Technologies
New York
|
-$436K |
| 3 |
NAH
Neumann Advisory (HK)
Central,
Hong Kong
|
-$430K |
| 4 |
SCP
Seizert Capital Partners
Birmingham,
Michigan
|
-$275K |
| 5 |
SIM
Spark Investment Management
New York
|
-$76.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $2K | +$548 | +75 | +29% |
|
|
GWM
27
Geneos Wealth Management
Englewood,
Colorado
| $1K | – | – | – |
|
|
28
Invesco
Atlanta,
Georgia
| – | -$619K | -81,265 | Closed |
|
|
SCP
29
Seizert Capital Partners
Birmingham,
Michigan
| – | -$275K | -36,062 | Closed |
|
|
AAMU
30
Amundi Asset Management US
Boston,
Massachusetts
| – | -$63K | -8,300 | Closed |
|
SVA Hedge Fund Activity: Q4 2018 in Review
27 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q4 2018, worth a combined $83.7M — down 10% from $93.4M a quarter earlier.
Fund positioning in SVA was balanced in Q4 2018: 3 funds opened new positions, 3 closed out, 6 added to existing stakes and 6 trimmed.
The largest buyer was State Street, adding an estimated $137K. The largest seller was Invesco, exiting entirely with an estimated $619K sold.
- 27 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q4 2018, down from 28 in Q3 2018.
- Funds reported $83.7M of Sinovac Biotech, Ltd stock for Q4 2018, down 10% quarter-over-quarter.
- 3 funds opened new Sinovac Biotech, Ltd positions in Q4 2018 and 3 closed out, a net change of 0 holders.
- The largest Sinovac Biotech, Ltd buyer in Q4 2018 was State Street, an estimated $137K added.
- The largest Sinovac Biotech, Ltd seller in Q4 2018 was Invesco, an estimated $619K sold.
Based on aggregated 13F filings for Q4 2018.